We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Crystal Structure Determined for Binding Site of Zika/Dengue Neutralizing Antibodies

By LabMedica International staff writers
Posted on 05 Jul 2016
An international team of molecular virologists has identified neutralizing antibodies that bind to and block both dengue virus and Zika virus, which may pave the way for development of a vaccine to protect against both viruses simultaneously.

The international team, headed by investigators at Institut Pasteur (Paris, France), examined the effect of two antibodies isolated from dengue patients on the Zika virus.

They reported in the June 23, 2016, online edition of the journal Nature that one of the antibodies was even better at neutralizing the Zika virus than it was at neutralizing dengue virus. More...
The X-ray crystal structure of the antibody in complex with the envelope protein of Zika virus revealed details of a conserved epitope, which was also the site of interaction of the envelope protein dimer with the precursor prM protein during virus maturation. This binding site on the Zika virus is the same as the one on the dengue virus, raising the possibility of producing a vaccine that would stimulate the production of antibodies capable of binding to and neutralizing both types of virus at the same time.

"We wanted to see whether the antibodies isolated for dengue could be used to neutralize other flaviviruses, and Zika seemed like the best candidate," said senior author Dr. Félix Rey, head of the structural virology laboratory at the Institut Pasteur. "We never expected to discover that the dengue virus and the Zika virus are so close that some antibodies produced against the dengue virus could also neutralize the Zika virus so potently. The antibodies could be used, for example, to protect pregnant women at risk of contracting the Zika virus, because there is currently no vaccine or treatment for this disease."

Related Links:
Institut Pasteur


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.